(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 June 2008 (19.06.2008)

PCT

(10) International Publication Number
WO 2008/071931 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61P 31/12* (2006.01)
A61K 31/4545 (2006.01)

(21) International Application Number:
PCT/GB2007/004716

(22) International Filing Date:
10 December 2007 (10.12.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/869,460 11 December 2006 (11.12.2006) US

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BROWN, Dearg, Sutherland** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **FAULL, Alan, Wellington** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **SWALLOW, Steven** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB).


(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(54) **Title:** PIPERIDINE DERIVATIVE USED FOR TREATING CHEMOKINE RECEPTOR 5 MEDIATED DISEASES



(I)

(57) **Abstract:** The present invention relates to 4-{(1*R*,3*R*)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5- isopropyl-4*H*- 1,2,4-triazol-4-yl)piperidin- 1 -yl]butyl} - 1 -(methylsulfonyl)piperidine formula (I) : or a pharmaceutically acceptable salt thereof, as well as to processes for preparing such a compound, to pharmaceutical compositions comprising such a compound and to the use of such a compound in the treatment of CCR5 mediated disease states.

WO 2008/071931 A1